In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Guidance programme

HealthTech approach

HealthTech approach

Area of interest

Showing 91 to 98 of 98

TitleTypeExpected publication date
Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6406]Technology appraisal guidance
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 therapies (MA review TA704 and TA862) [ID5121]Technology appraisal guidanceTBC
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]Technology appraisal guidanceTBC
Trilaciclib for preventing myelosuppression caused by chemotherapy for extensive-stage small-cell lung cancer [ID6651]Technology appraisal guidanceTBC
Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]Technology appraisal guidanceTBC
Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]Technology appraisal guidanceTBC
Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [ID6444]Technology appraisal guidanceTBC
Zongertinib for treating HER2-mutated unresectable or metastatic non-small-cell lung cancer ID6573Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All